The DOI matches its Crossref record.
Effects of the soluble guanylyl cyclase activator, YC‐1, on vascular tone, cyclic GMP levels and phosphodiesterase activity
Open accessAbstract
The vasomotor and cyclic GMP‐elevating activity of YC‐1, a novel NO‐independent activator of soluble guanylyl cyclase (sGC), was studied in isolated rabbit aortic rings and compared to that of the NO donor compounds sodium nitroprusside (SNP) and NOC 18. Similarly to SNP and NOC 18, YC‐1 (0.3–300 μ M) caused a concentration‐dependent, endothelium‐independent relaxation that was greatly reduced by the sGC inhibitor 1‐H‐[1,2,4]oxadiazole[4,3‐a]quinoxalin‐1‐one (ODQ 10 μ M; 59% inhibition of dilation induced by 100 μ M YC‐1) suggesting the activation of sGC as one mechanism of action. Preincubation with YC‐1 (3 and 30 μ M) significantly increased the maximal dilator responses mediated by endogenous NO in aortic rings that was released upon exposure to acetylcholine, and enhanced the dilator response to the exogenous NO‐donors, SNP and NOC 18, by almost two orders of magnitude. Vasoactivity induced by SNP and YC‐1 displayed different kinetics as evidenced by a long‐lasting inhibition by YC‐1 (300 μ M) on the phenylephrine (PE)‐induced contractile response, which was not fully reversible even after extensive washout (150 min) of YC‐1, and was accompanied by a long‐lasting elevation of intracellular cyclic GMP content. In contrast, SNP (30 μ M) had no effect on the vasoconstrictor potency of PE, and increases in intravascular cyclic GMP levels were readily reversed after washout of this NO donor compound. Surprisingly, YC‐1 not only activated sGC, but also affected cyclic GMP metabolism, as it inhibited both cyclic GMP break down in aortic extracts and the activity of phosphodiesterase isoforms 1–5 in vitro. In conclusion, YC‐1 caused persistent elevation of intravascular cyclic GMP levels in vivo by activating sGC and inhibiting cyclic GMP break down. Thus, YC‐1 is a highly effective vasodilator compound with a prolonged duration of action, and mechanisms that are unprecedented for any previously known sGC activator. British Journal of Pharmacology (1999) 127, 195–203; doi:10.1038/sj.bjp.0702495
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Concepts of neural nitric oxide‐mediated transmission
Garthwaite, J. (2008) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2008.06285.x · Cited by 807
Evgenov, O. V., Pacher, P., Schmidt, P. M., Haskó, G., Schmidt, H. H. H. W., & Stasch, J.-P. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2038 · Cited by 749
Self-citationSoluble Guanylate Cyclase as an Emerging Therapeutic Target in Cardiopulmonary Disease
Stasch, J.-P., Pacher, P., & Evgenov, O. V. (2011) · Circulation · doi:10.1161/circulationaha.110.981738 · Cited by 601
NO-independent regulatory site on soluble guanylate cyclase
Stasch, J.-P., Becker, E. M., Alonso-Alija, C., Apeler, H., Dembowsky, K., Feurer, A., Gerzer, R., Minuth, T., Perzborn, E., Pleiß, U., et al. (2001) · Nature · doi:10.1038/35065611 · Cited by 545
Sources of Vascular Nitric Oxide and Reactive Oxygen Species and Their Regulation
Tejero, J., Shiva, S., & Gladwin, M. T. (2019) · Physiological Reviews · doi:10.1152/physrev.00036.2017 · Cited by 541
Regulation of Nitric Oxide-Sensitive Guanylyl Cyclase
Friebe, A., & Koesling, D. (2003) · Circulation Research · doi:10.1161/01.res.0000082524.34487.31 · Cited by 508
YC-1: A Potential Anticancer Drug Targeting Hypoxia-Inducible Factor 1
Yeo, E.-J., Chun, Y.-S., Cho, Y.-S., Kim, J., Lee, J.-C., Kim, M.-S., & Park, J.-W. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.7.516 · Cited by 476
The Concise Guide to PHARMACOLOGY 2013/14: Enzymes
Alexander, S. P. H., Benson, H. E., Faccenda, E., Pawson, A. J., Sharman, J. L., Spedding, M., Peters, J. A., Harmar, A. J., & Collaborators, C. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12451 · Cited by 425
Vasoactive properties of CORM‐3, a novel water‐soluble carbon monoxide‐releasing molecule
Foresti, R., Hammad, J., Clark, J. E., Johnson, T. R., Mann, B. E., Friebe, A., Green, C. J., & Motterlini, R. (2004) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705825 · Cited by 303
Chun, Y.-S., Yeo, E.-J., Choi, E., Teng, C.-M., Bae, J.-M., Kim, M.-S., & Park, J.-W. (2001) · Biochemical Pharmacology · doi:10.1016/s0006-2952(01)00564-0 · Cited by 151
Nitric oxide in the pulmonary vasculature
Coggins, M. P., & Bloch, K. D. (2007) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.107.142943 · Cited by 138
Stasch, J., Dembowsky, K., Perzborn, E., Stahl, E., & Schramm, M. (2002) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704483 · Cited by 120
Nox1, 2, 4, 5: Counting out oxidative stress
Wingler, K., Hermans, J., Schiffers, P., Moens, A., Paul, M., & Schmidt, H. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01249.x · Cited by 113
“The original compound, YC-1 had still some off-target effects (Galle et al., 1999; Li et al., 2008).”
Self-citationGarthwaite, J. (2010) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-009-0318-8 · Cited by 102
Pharmacology and Clinical Drug Candidates in Redox Medicine
Dao, V. T.-V., Casas, A. I., Maghzal, G. J., Seredenina, T., Kaludercic, N., Robledinos-Anton, N., Di Lisa, F., Stocker, R., Ghezzi, P., Jaquet, V., et al. (2015) · Antioxidants & Redox Signaling · doi:10.1089/ars.2015.6430 · Cited by 88
Self-citationHypoxia-inducible factor inhibitors: a survey of recent patented compounds (2004 - 2010)
Ban, H. S., Uto, Y., & Nakamura, H. (2011) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2011.547477 · Cited by 42
Liu, Y.-N., Pan, S.-L., Peng, C.-Y., Guh, J.-H., Huang, D.-M., Chang, Y.-L., Lin, C.-H., Pai, H.-C., Kuo, S.-C., Lee, F.-Y., et al. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.090563 · Cited by 36
Metadata
- Authors
- Galle, J., Zabel, U., Hübner, U., Hatzelmann, A., Wagner, B., Wanner, C., & Schmidt, H. H. H. W.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 1999-05
- Volume
- 127
- Issue
- 1
- Pages
- 195-203
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2069881405
- Cited by
- 173
- References
- 0
- FWCI
- 4.35
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.